تحميل...
Prevalence of CYP2C8*2 and *3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment
BACKGROUND: In Eritrea, artesunate–amodiaquine is the first-line treatment against uncomplicated malaria. Amodiaquine, which is mainly bio-transformed by CYP2C8, is known to be associated with adverse events of different severity. Extrapyramidal events are among the less common but have been reporte...
محفوظ في:
| الحاوية / القاعدة: | Pharmgenomics Pers Med |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Dove
2020
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7669516/ https://ncbi.nlm.nih.gov/pubmed/33209048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S276215 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|